The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 247 participants.

Also called NCT02558231

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 247 participants (enrolled count) (from the registry)
Sponsor
  • Actelion Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02558231
Other papers using this trial's data
  • Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension Journal of the American College of Cardiology, 2021-10-05 DOI, PubMed 34593120

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02558231. Randomized; quadruple masking; primary purpose treatment. Start 2016-05-01 (actual); primary completion 2019-08-29 (actual). Results posted on 2020-09-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
Acronym
TRITON
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
Macitentan
Intervention (Drug)
Tadalafil
Intervention (Drug)
Selexipag
Lead sponsor
Actelion (class: industry)

Record details

Record id
cardio:ct-nct02558231
Content hash
12053417bc38169c675d5ab60221360c6ab41ae21e7e769edcf26f5236f7b6bb